Altimmune Inc (ALT) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Biotechnology industry.
Over the past 4 years, Altimmune Inc has achieved a revenue compound annual growth rate (CAGR) of -77.8%, while earnings have grown at 18.0% CAGR.
Historical revenue and profitability trends for Altimmune Inc
The chart above illustrates Altimmune Inc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Altimmune Inc's business.
How efficiently Altimmune Inc converts revenue into profit
Profit margins reveal how much of each dollar of revenue Altimmune Inc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Altimmune Inc to continue focusing on sustainable operations. The consensus analyst rating is 4.4444 based on 9 analysts.
Based on our comprehensive analysis, Altimmune Inc (ALT) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Altimmune Inc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Altimmune Inc stacks up against similar companies
Explore growth analysis for top stocks
Related: ALT Valuation, ALT Dividend, ALT Financial Health
Compare: ALT vs AAPL, ALT vs MSFT, ALT vs GOOGL